Sony Updates NUCLeUS Medical Imaging Platform to Support Remote Patient Observation

Sony Updates NUCLeUS Medical Imaging Platform to Support Remote Patient Observation

What You Should Know:

– Today, Sony announced an update to our NUCLeUS medical
imaging platform, which improves support for remote patient observation.

– NUCLeUS has added new functionality and features,
including powerful bi-directional telestration capabilities allowing multiple
remote users to simultaneously annotate, draw or highlight areas of interest in
a live stream video or still image.

Sony today
announced an update to its vendor-neutral medical imaging platform NUCLeUS. The latest release introduces Remote
Patient Monitoring (observation) functionality with recording functionalities
for use in the operating room (OR), Intensive Care Units (ICU), endoscopy
suites, procedure rooms or anywhere else in the hospital.

The Smart Digital Imaging Platform for Medical Environments

Sony Updates NUCLeUS Medical Imaging Platform to Support Remote Patient Observation

Developed in consultation with leading surgeons and with vendor
neutrality in mind, NUCLeUS guides clinical staff through the planning,
recording and sharing of video, still images and other patient-related data.
Seamlessly linking Sony and third-party devices, applications, video and most
importantly, people, NUCLeUS focuses on hospital staff requirements and use
cases, adding value to imaging workflows.

New
Bi-Directional Telestration Capabilities

NUCLeUS has added
new functionality and features, including powerful bi-directional telestration
capabilities allowing multiple remote users to simultaneously annotate, draw or
highlight areas of interest in a live stream video or still image. This can be
securely shared with authorized viewers to discuss as a group in real time,
ideally suited for socially distanced environments.  Equipped with a full
set of recording functionalities, NUCLeUS is also a valuable tool for
hospitals, outpatient surgery centers and private practices serving a variety
of specialties including Urology, ENT, Obstetrics, Ophthalmic, Plastic surgery,
and Robotics

New NUCLeUS Functionality Features

New functionalities of NUCLeUS include:

Mosaic
Video Wall,

presenting video streams from image sources in multiple ORs and ICUs
simultaneously on a single display, thus providing a situational overview of
activity in a tiled or mosaic format.

An
iPad Streaming function,
allowing clinical staff to access images from any modality via
an iPad in virtual real time within the OR, so medical staff can follow the
intervention on their handheld device.

High
quality 4K conversion
, allowing any HD resolution video content to be converted to 4K
using advanced resolution-augmentation algorithms superior to conventional
upscaling, giving a crisp ultra-high resolution view of converted video
footage.

Customizable
Expanded Patient Distraction
– helping to reduce patient anxiety through music tracks and
video imagery that can be played in the OR to create a more relaxing and
comfortable atmosphere.

Patient
Time-Out Functionality
, featuring checklists that simplify time out of safety
standards at the start, during and end of an operation.

Enhanced
Printing capabilities
, allowing hard copies of still images captured by NUCLeUS to be
created inside the OR using an optional UP-DR80MD A4 digital color printer. The
Auto Print function also extends CMS (Content Management System) print
functionality to collect a preconfigured number of stills, printing them
automatically.

Full
compatibility
with the latest Sony PTZ and fixed cameras including HD and 4K
models.

“Sony is committed to developing NUCLeUS to suit the needs of patients and medical staff at all times,” said Theresa Alesso, pro division President, Sony Electronics.  “The Remote Patient Monitoring capabilities within NUCLeUS are a primary example of this and were developed to help hospitals manage day-to-day requirements through the COVID-19 pandemic.  We are committed to helping hospitals and healthcare providers reinvent their workflows and provide medical staff with the tools they need to continue delivering excellent patient care.”

KēlaHealth Lands $12.9M to Expand AI-Powered Surgical Intelligence Platform

KēlaHealth Lands $12.9M to Expand Surgical AI Platform

What You Should Know:

–  KēlaHealth
announced their Series A round (combined seed and Series A) of $12.9M led by
Sante Ventures and new innovation VC, Intuitive Ventures.

– KēlaHealth, is a surgical intelligence engine that
applies a dynamic cycle of patient-specific predictions, stratified
interventions, and outcomes tracking to reduce surgical complications

– KēlaHealth is the first investment for Intuitive
Ventures, a new innovation fund spun out of Intuitive Surgical, Inc.


KēlaHealth, Inc.,
a San Francisco, CA-based surgical intelligence platform that applies a dynamic
cycle of patient-specific predictions, stratified interventions, and outcomes
tracking to reduce surgical complications, today announced the closing of
a $2.9 million Seed financing and milestone-based $10 million Series
A financing led by Santé Ventures and Intuitive Ventures, and inclusive of grant
funding from the National Science Foundation Small Business Innovation Research
(SBIR) Program. These funds will accelerate the expansion of the KēlaHealth
platform to hospitals and surgical partners across the United States. KēlaHealth
is the first investment for Intuitive Ventures, a new innovation fund spun out
of Intuitive Surgical, Inc.

Learning Ecosystem to Improve Surgical Care Outcomes

Founded by Bora Chang, MD, with a goal of harnessing machine
learning algorithms to reduce patient surgical complications and improve
outcomes. KēlaHealth uses advanced artificial intelligence techniques to
deliver a cloud-based software-as-a-service solution to healthcare providers,
surgeons, and hospital systems.

In the U.S., 51 million surgeries are performed annually, with an average complication rate of 15 percent. This results in millions of patients suffering harm and loss after a procedure. Tragically, half of these complications are known to be avoidable and contribute to $77 billion in wasted healthcare costs each year

KēlaHealth helps to prevent these avoidable complications
while enhancing surgical care by delivering stratified patient risk scoring.
The company’s state-of-the-art platform uses machine learning algorithms to
match individual risk levels with graduated pathways of care that align with
the unique needs of each surgical patient.

These personalized efforts bring surgery into a new era of
precision medicine: with KēlaHealth, surgeons can match the right patient with
the right procedure with the right precautions at the right time, leading to
improved patient outcomes and significant hospital savings.

To date, KēlaHealth’s hospital partners have applied the
company’s AI-powered platform in colorectal, vascular, cardiac, and orthopedics
surgical specialties.

The company has participated in highly selective accelerator
programs such as Cedars-Sinai Techstars Accelerator, Healthbox Studio, and Plug
and Play.

Dr. Chang, CEO of KēlaHealth added: “Our vision is to apply the lessons learned from millions of previous surgeries for the benefit of every patient undergoing a procedure. Patients and their families, clinicians, and hospitals deserve the assurance that the risks of any surgery will be safely navigated by surgical teams with the best information available to them at every point in the surgical journey. We are thrilled to have a stellar group of surgeons, hospital centers, investors, and advisors working with us to realize the opportunity of precision surgery.”

Activ Surgical Raises $15M Advance Autonomous and Collaborative Surgery

Activ Surgical Raises $15M Advance Autonomous and Collaborative Surgery

What You Should Know:

– Digital surgery pioneer Activ Surgical raises $15M in funding led by ARTIS Ventures to accelerate U.S. commercialization and European expansion efforts for its ActiveEdge platform, which enables existing surgical systems, from scopes to robots, to visualize, characterize and track tissue, in real-time beyond today’s human capability. 

– ActivSight, is an easy-to-adapt, connected imaging module that seamlessly attaches to today’s laparoscopic and arthroscopic systems so outcomes can be improved immediately, providing real-time, on-demand insights, integrated into standard monitors.

– The company is aiming for FDA clearance in Q4 this year
and already has eight hospital systems in the US signed up for pilot programs.


Activ Surgical™, a Boston, MA-based digital surgery pioneer, today announced the close of a $15 million venture round led by ARTIS Ventures, a venture firm focused on pioneering investments at the intersection of life sciences and computer sciences. LRVHealth, the “Inside Healthcare” venture capital platform, joined the round, along with participation from existing investors DNS CapitalGreatPoint Ventures (GPV)Tao Capital Partners, and Rising Tide VC. To date, Activ Surgical has raised a total of $32 million.

ActivSight: Reveal Game-Changing Visual Data During Surgery

Founded in 2017, Activ Surgical is building a
hardware-agnostic platform to enable autonomous and collaborative surgery
through the integration of computer vision, artificial intelligence and
robotics. The company’s first product in the portfolio, ActivSight, is an
easy-to-adapt, connected imaging module that seamlessly attaches to today’s
laparoscopic and arthroscopic systems so outcomes can be improved immediately,
providing real-time, on demand insights, integrated into standard
monitors. The company’s second product currently in development,
ActivInsight will transform massive amounts of surgical data into intelligent,
real-time guidance for surgeons over the next 12 months.

Preventable medical errors are the third leading cause of
death after heart attack and cancer, with preventable surgical errors costing
U.S. health care $36B+ and 400k+ deaths every year. Activ Surgical’s
patent-protected surgical software platform reduces unintended and preventable
surgical complications by enhancing a surgeon’s intra-operative decision
making. In 2018, Activ Surgical completed the world’s first fully autonomous
minimally invasive robotic surgery of soft tissue.

Expansion Plans

Activ Surgical will use proceeds of the latest financing round to accelerate U.S. commercialization and European expansion efforts for itsActivEdge™ platform, which enables existing surgical systems, from scopes to robots, to visualize, characterize and track tissue, in real-time beyond today’s human capability. The company is aiming for FDA clearance in Q4 this year and already has eight hospital systems in the US signed up for pilot programs.

“Activ Surgical is poised to play a leading role in the democratization of surgical care, extending insights from experienced surgeons to surgical systems all over the globe, and ensuring world-class care for all, regardless of location,” said Todd Usen, CEO, Activ Surgical. “We welcome the guidance and support from our new and current investors and Board members as we accelerate our efforts to commercialize our first product, ActivSight. 2020 will be pivotal for our business with committed pilot projects with major hospital systems slated to launch by the end of this year.”